Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an announcement.
On July 18, 2025, Telomir Pharmaceuticals, Inc. sold 1,100,000 shares of its common stock to institutional investors, raising approximately $2.9 million through its at-the-market equity offering facility. This move, facilitated by Rodman & Renshaw via the StockBlock platform, was executed at a premium to the prior day’s closing price, potentially strengthening the company’s financial position.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and sale of pharmaceutical products.
Average Trading Volume: 3,081,875
Technical Sentiment Signal: Sell
Current Market Cap: $67.86M
For a thorough assessment of TELO stock, go to TipRanks’ Stock Analysis page.